| Online-Ressource |
Verfasst von: | Wannhoff, Andreas [VerfasserIn]  |
| Brune, Maik [VerfasserIn]  |
| Knierim, Johannes [VerfasserIn]  |
| Weiss, Karl Heinz [VerfasserIn]  |
| Rupp, Christian [VerfasserIn]  |
| Gotthardt, Daniel [VerfasserIn]  |
Titel: | Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis |
Verf.angabe: | Andreas Wannhoff, Maik Brune, Johannes Knierim, Karl Heinz Weiss, Christian Rupp, Daniel N. Gotthardt |
E-Jahr: | 2019 |
Jahr: | 27 January 2019 |
Umfang: | 10 S. |
Fussnoten: | Gesehen am 01.04.2019 |
Titel Quelle: | Enthalten in: Alimentary pharmacology & therapeutics |
Ort Quelle: | Oxford : Blackwell Science, 1987 |
Jahr Quelle: | 2019 |
Band/Heft Quelle: | 49(2019), 6, Seite 769-778 |
ISSN Quelle: | 1365-2036 |
Abstract: | Background Primary sclerosing cholangitis is associated with an increased risk of biliary tract cancer. Carbohydrate antigen 19-9 (CA19-9) can be used to screen for these malignancies. Aim To perform a longitudinal analysis of CA19-9 in patients with primary sclerosing cholangitis. Methods We conducted a retrospective analysis of CA19-9 values in patients who had primary sclerosing cholangitis, with and without biliary malignancy. We calculated the index of individuality and reference change value in patients who were cancer-free. Long-term analysis of CA19-9 in cancer-free patients was performed and we assessed the change of CA19-9 prior to diagnosis of cancer. Results We obtained 1818 CA19-9 values from 247 patients, including 32 with malignancy. Median CA19-9 in cancer-free individuals was 15.6 U/mL. The index of individuality was 0.37 and the reference change value was 46.23%. In cancer-free patients, no significant change in CA19-9 was observed at 1, 2, 5, 7, 10, 15, and 20 years after initial diagnosis of primary sclerosing cholangitis. In patients with biliary tract cancer, CA19-9 was higher at 3 months prior to diagnosis (P < 0.05) than at 6 months before diagnosis and was also higher than at 3 months prior to last follow-up in cancer-free patients (P < 0.05). In 92.9% of patients with biliary cancer, we found an increase in CA19-9 of >46.23% in the year prior to cancer diagnosis. Conclusions CA19-9 in patients with primary sclerosing cholangitis is highly individual, and the reference change value should be preferred to reference intervals. In this study, CA19-9 remained stable in patients who were cancer-free but increased early in those who developed biliary tract cancer. Regular CA19-9 measurement might improve early detection of these malignancies. |
DOI: | doi:10.1111/apt.15146 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1111/apt.15146 |
| Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.15146 |
| DOI: https://doi.org/10.1111/apt.15146 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1662607059 |
Verknüpfungen: | → Zeitschrift |
Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis / Wannhoff, Andreas [VerfasserIn]; 27 January 2019 (Online-Ressource)